Trillium Therapeutics Inc. Company Profile

05:18 EDT 26th September 2017 | BioPortfolio

News Articles [1534 Associated News Articles listed on BioPortfolio]

Trillium Therapeutics publicly sells common and preferred shares, nets $28.2mm

Trillium Therapeutics Inc. (immuno-oncology) netted $28.2mm through the public sale of 2.75mm common shares at $5 and 3.25mm Series II non-voting convertible first preferred shares at $5. Proceeds wil...

Trillium Therapeutics Reports Second Quarter 2017 Financial and Operating Results / Clinical responses observed in Phase 1 trial of TTI-621; Scope of trial expanded, including dose-intensification strategy; $39 million capital raise; cash and marketable

TORONTO, ONTARIO -- (Marketwired) -- 08/11/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...

Trillium Issues Update on Small Molecule Preclinical Programs

NewsTrillium has launched a discovery program that is focused on an undisclosed early-stage immuno-oncology target.

Trillium Therapeutics Announces Presentation on TTI-621 Immune Checkpoint Inhibitor Targeting CD47 at 2017 ASCO Annual Meeting

TORONTO, ONTARIO -- (Marketwired) -- 05/31/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of c...

Trillium Therapeutics Inc TR Financial and Strategic SWOT Analysis Review [Report Updated: 28062017] Prices from USD $125

Trillium Therapeutics Inc TR Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by ...

Trillium raises $30M in follow-on and preferred stock

Trillium Expands Clinical Trial With TTI-621 to Include Combination With PD-1 Blockade

TORONTO, ONTARIO -- (Marketwired) -- 06/07/17 -- Trillium Therapeutics Inc. (NASDAQ: TRIL)(TSX: TRIL), a clinical stage immuno-oncology company, today announced that based upon promising early eviden...

Concurrent with BMS acquisition, IFM Therapeutics spins off IFM Therapeutics LLC

Innate immunity-focused IFM Therapeutics is spinning off its non-oncology assets into the new company IFM Therapeutics LLC.

Clinical Trials [117 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1150 Associated Companies listed on BioPortfolio]

Trillium Therapeutics Inc

Trillium Therapeutics Inc. (TTI), a research-driven biopharmaceutical company with a strong immunology focus, specializes in the discovery and development of innovative therapies for the treatment of ...

Trillium Therapeutics Inc.

Trillium Medical Ventures, LLC

Trillium Medical Ventures, LLC, a bio science technology assessment firm founded in 1998, evaluates life science intellectual property and technology with the objective of identifying unique and valua...

Aeris Therapeutics

Aeris Therapeutics is an emerging medical therapeutics company specializing in the development and commercialization of novel treatments for patients with emphysema and other adva...

Altair Therapeutics, Inc.

Based in San Diego, Altair Therapeutics, Inc. is a privately-held biopharmaceutical company developing novel therapeutics to treat human respiratory diseases. Altair Therap...

More Information about "Trillium Therapeutics Inc." on BioPortfolio

We have published hundreds of Trillium Therapeutics Inc. news stories on BioPortfolio along with dozens of Trillium Therapeutics Inc. Clinical Trials and PubMed Articles about Trillium Therapeutics Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Trillium Therapeutics Inc. Companies in our database. You can also find out about relevant Trillium Therapeutics Inc. Drugs and Medications on this site too.

Quick Search

Corporate Database Quicklinks

Searches Linking to this Company Record